Industry: Health care Region: Austria Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
An Austrian company is committed to rigorous testing and discovery of new drugs by using a new generation of stem cell technology. These test procedures can protect patients from harmful side effects. Team members have expertise in stem cells and cardiovascular diseases. The company is developing a cardiotoxicity test that can be used to test the effect of drugs. Using vascular cells, myocardial cells and epicardial cells in Petri dishes to replicate drug reactions similar to human body. In this way, side effects such as heart attack, stroke, high blood pressure and dangerous arrhythmia can be predicted more accurately.
Enterprise technical advantages:
1. Safer drugs
The company uses a new generation of stem cell technology to strictly screen new drug compounds. This can prevent patients from being affected by harmful side effects.
2. Reduce the cost of drug development
The company's technology can detect the side effects of drugs early when the compounds are still in the development stage, thus reducing the consequences of side effects during clinical trials or even after approval. In addition, more accurate detection can also reduce the risk of giving up potential candidate drugs by mistake in drug development.
Cooperation mode:
To seek China's partners who need new drug testing and screening technology in the field of drug research and development and production.